ASCO issued an alert regarding dwindling supplies of ifosfamide, which is used across testicular cancer and sarcoma regimens.

Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.

The FDA has granted 68Ga-NYM096 breakthrough therapy and fast track designations for imaging ccRCC.

Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR TKI–pretreated advanced clear cell renal cell carcinoma.